pharma · Plaque Psoriasis · Moderate-to-Severe Plaque Psoriasis · ORKA
Oruka Therapeutics
Oruka Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker ORKA. Primary therapeutic focus areas include Plaque Psoriasis, Moderate-to-Severe Plaque Psoriasis. NovaPharmaNew
Waltham, USA HQ
78 Employees
Public company Type
ORKA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Employees
- 78
- Programs
- 6
- Drugs
- 3
- Patents
- 0
ORKA-002
Phase 2 · small molecule · Plaque Psoriasis
ORKA-002 for Plaque Psoriasis is a Phase 2 program (small_molecule) at Oruka Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ORKA-002-212
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Oruka Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Plaque Psoriasis
- Status
- active
- Trials
- 1